Showing results (51-60 of 3,155) with videos related to

Sort By:
Pageof 316
Translational Oncology|April 26, 2022
Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumorsMax J Cotler, Khalil B Ramadi, Xiaonan Hou, et al.
Translational Oncology|March 27, 2022
LncRNA GIHCG promoted the proliferation and migration of renal cell carcinoma through regulating miR-499a-5p/XIAP axisShu-Ying Zhu, Hong-Chang Zou, Ming-Ming Gao, et al.
Translational Oncology|April 16, 2022
TSPAN31 regulates the proliferation, migration, and apoptosis of gastric cancer cells through the METTL1/CCT2 pathwayXiang Ma, Shipei Qiu, Xin Tang, et al.
Translational Oncology|October 14, 2021
68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional studyJuana Martinez, Kritika Subramanian, Daniel Margolis, et al.
Translational Oncology|October 9, 2021
Comparative mRNA/micro-RNA co-expression network drives melanomagenesis by promoting epithelial-mesenchymal transition and vasculogenic mimicry signalingWenFeng He, Gang Yang, Shuya Liu, et al.
Translational Oncology|October 10, 2021
Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysisYanmei Dai, Huijie Jiang, Hao Jiang, et al.
Translational Oncology|October 17, 2021
Optimizing outcomes in HCC: Comment on "optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et alAlessandro Rizzo
Translational Oncology|February 19, 2022
Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of gliomaMari Kogiso, Lin Qi, Yuchen Du, et al.
Translational Oncology|April 13, 2022
Myoepithelial carcinoma of major salivary glands: Analysis of population-based clinicopathologic and prognostic featuresYunxiu Luo
Translational Oncology|February 3, 2022
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AMLKotoko Yamatani, Tomohiko Ai, Kaori Saito, et al.
Pageof 316